Regeneron Pharmaceuticals
Regeneron is seeking a 2027 Co-op to join the VelociGene team, contributing to the development of next-generation gene-editing tools and proprietary platforms for cell lines, mouse models, and therapeutics. The role involves screening engineered protein variants, applying computational structure-prediction tools, and performing molecular biology and cell culture techniques. This full-time, onsite position offers the opportunity to make a meaningful difference to patients worldwide while collaborating with scientists across the team.
Headquarters
Tarrytown, New York, United States
Company Size
10001+ employees
Founded
1988
Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.
Quadrant Capital Group LLC Purchases 1,564 Shares of Regeneron Pharmaceuticals, Inc. $REGN
4 hours ago
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
6 hours ago
Will Positive Obesity Data and Dupixent Expansion Efforts Change Regeneron Pharmaceuticals' (REGN) Narrative?
1 day ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Regeneron Pharmaceuticals.
Regeneron: Fairly Valued Now After A Stellar Upswing (NASDAQ:REGN)
1 day ago
Research Assistant
Salk Institute
Associate Scientist I / Bench Scientist
Integrated Resources INC
Associate Scientist / Bench Scientist
Integrated Resources INC
Senior Research Associate, In Vivo Discovery
Pivotal
Research Associate I – Molecular Anatomy – Genome Engineering
The Allen Institute for Artificial Intelligence
Research Associate
University of Colorado